![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee
Sildenafil, tadalafil, and vardenafil each competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accumulation and relaxation of vascular smooth muscle. Biochemical potencies (affinities) of these compounds for PDE5 determined by IC50, KD (isotherm), KD (dissociation rate), and KD (
EC50), respectively, were the following: sildenafil (3.7 ± 1.4, 4.8 ± 0.80, 3.7 ± 0.29, and 11.7 ± 0.70 nM), tadalafil (1.8 ± 0.40, 2.4 ± 0.60, 1.9 ± 0.37, and 2.7 ± 0.25 nM); and vardenafil (0.091 ± 0.031, 0.38 ± 0.07, 0.27 ± 0.01, and 0.42 ± 0.10 nM). Thus, absolute potency values were similar for each inhibitor, and relative potencies were vardenafil >> tadalafil > sildenafil. Binding of each 3H inhibitor to PDE5 was specific as determined by effects of unlabeled compounds. 3H Inhibitors did not bind to isolated PDE5 regulatory domain. Close correlation of EC50 values using all three 3H inhibitors competing against one another indicated that each occupies the same site on PDE5. Studies of sildenafil and vardenafil analogs demonstrated that higher potency of vardenafil is caused by differences in its double ring. Exchange-dissociation studies revealed two binding components for each inhibitor. Excess unlabeled inhibitor did not significantly affect 3H inhibitor dissociation after infinite dilution, suggesting the absence of subunit-subunit cooperativity. cGMP addition increased binding affinity of [3H]tadalafil or [3H]vardenafil, an effect presumably mediated by cGMP binding to PDE5 allosteric sites, implying that either inhibitor potentiates its own binding to PDE5 in intact cells by elevating cGMP. Without inhibitor present, cGMP accumulation would stimulate cGMP degradation, but with inhibitor present, this negative feedback process would be blocked.
Received January 21, 2004; accepted April 9, 2004.
Address correspondence to: Dr. Jackie D. Corbin, 702 Light Hall, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615. E-mail: jackie.corbin{at}mcmail.vanderbilt.edu
This article has been cited by other articles:
|
|
 |
|
  Y.-T. Liu, S. L. Matte, J. D. Corbin, S. H. Francis, and R. H. Cote Probing the Catalytic Sites and Activation Mechanism of Photoreceptor Phosphodiesterase Using Radiolabeled Phosphodiesterase Inhibitors J. Biol. Chem., November 13, 2009; 284(46): 31541 - 31547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Weeks II, J. D. Corbin, and S. H. Francis Interactions between Cyclic Nucleotide Phosphodiesterase 11 Catalytic Site and Substrates or Tadalafil and Role of a Critical Gln-869 Hydrogen Bond J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 133 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Halvey, J. Vernon, B. Roy, and J. Garthwaite Mechanisms of Activity-dependent Plasticity in Cellular Nitric Oxide-cGMP Signaling J. Biol. Chem., September 18, 2009; 284(38): 25630 - 25641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Zhang, K. B. Cahill, A. Elfenbein, V. Y. Arshavsky, and R. H. Cote Direct Allosteric Regulation between the GAF Domain and Catalytic Domain of Photoreceptor Phosphodiesterase PDE6 J. Biol. Chem., October 31, 2008; 283(44): 29699 - 29705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Bessay, M. A. Blount, R. Zoraghi, A. Beasley, K. A. Grimes, S. H. Francis, and J. D. Corbin Phosphorylation Increases Affinity of the Phosphodiesterase-5 Catalytic Site for Tadalafil J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 62 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lubamba, H. Lecourt, J. Lebacq, P. Lebecque, H. De Jonge, P. Wallemacq, and T. Leal Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 506 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Blount, R. Zoraghi, E. P. Bessay, A. Beasley, S. H. Francis, and J. D. Corbin Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 730 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Blount, R. Zoraghi, H. Ke, E. P. Bessay, J. D. Corbin, and S. H. Francis A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization Mol. Pharmacol., November 1, 2006; 70(5): 1822 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zoraghi, J. D. Corbin, and S. H. Francis Phosphodiesterase-5 Gln817 Is Critical for cGMP, Vardenafil, or Sildenafil Affinity: ITS ORIENTATION IMPACTS cGMP BUT NOT cAMP AFFINITY J. Biol. Chem., March 3, 2006; 281(9): 5553 - 5558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Teixeira, F. B. M. Priviero, and R. C. Webb Differential Effects of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, and Tadalafil in Rat Aorta J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 654 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, Q. Feng, and R. H. Cote Efficacy and Selectivity of Phosphodiesterase-Targeted Drugs in Inhibiting Photoreceptor Phosphodiesterase (PDE6) in Retinal Photoreceptors Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3060 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Lincoln Cyclic GMP and Phosphodiesterase 5 Inhibitor Therapies: What's on the Horizon? Mol. Pharmacol., July 1, 2004; 66(1): 11 - 13. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
